In preclinical models, abnormal activation of the IGF-1R signaling pathway is considered one of the mechanisms by which NSCLC cells develop resistance to first- and second-generation EGFR TKIs via bypass pathways. This evidence concerns the gene EGFR and non-small cell lung carcinoma.